Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
International FOP Association, Inc. Summary Contact Information Nonprofit International FOP Association, Inc. Address 101 Sunnytown Road Suite 208 Casselberry, FL 32707 Phone (407) 365-4194 Fax (407) 365-3213 Web Site www.ifopa.org At a Glance IRS Ruling Year 1988 Organization's type of tax exempt status Public Supported Charity 1 Statements Statements Mission Fund research to find a cure for Fibrodysplasia Ossificans Progressiva while supporting individuals and their families through education, public awareness and advocacy. Impact A constant focus of the IFOPA is funding for FOP research being conducted at the FOP Laboratory at the University of Pennsylvania School of Medicine. Funding for this research has led to the discovery of the gene that causes FOP. Funding is also provided to FOP researchers and institutions through the Competitive Research Grant. Applications are reviewed by a Scientific Advisory Board for approval, funding is provided at milestone markers throughout the research efforts. In July 2015, the IFOPA launched the FOP Connection Registry with the following objectives in mind: • To organize the international FOP community for potential participation in clinical trials or other research studies • To enable FOP patients worldwide to report data on their own disease state in a shared forum, ultimately empowering both individual patients and the community as a whole • To improve the collective understanding of FOP natural history and its functional, emotional, and psychological impact over time, and when treatments are available • To advance the understanding of FOP treatment outcomes. One year later, the Registry has 178 individuals with FOP enrolled from 28 countries and we expect enrollment to increase rapidly as we introduce the registry in several languages over the latter half of 2016 and into 2017. The IFOPA continues to focus on translating and distributing the IFOPA Medical Binder to international individuals with FOP who speak Dutch, French, German, Hindi, Italian, Polish and Spanish. The website is being redesigned to provide FOP individuals with an online directory of personal contact information, serve as a better fundraising platform and help to spread awareness of this very rare condition, FOP. Needs The primary needs of the International FOP Association are funding to support FOP research and member programs, volunteers to assist with fundraisers and opportunities to provide awareness and education to physicians, healthcare facilities and communities worldwide. Background The International FOP Association (IFOPA) was founded in 1988 as a support organization allowing people who have FOP, Fibrodysplasia Ossificans Progressiva, and their families to share information, support medical research, and educate physicians and other interested individuals about FOP. FOP is a rare disease in which normal bone grows in abnormal locations, such as muscles, ligaments, tendons, and other connective tissues. The difficulties of FOP are magnified by the isolation of having a condition that occurs in only one in two million births. Prior to the creation of the IFOPA, most of those suffering the consequences of FOP did so without ever knowing another person with FOP for guidance and commiseration. In addition to creating and maintaining the FOP Research Lab, the IFOPA works to minimize the suffering of those with FOP by providing a forum for the exchange of ideas, emotional support, coping mechanisms, experiences and more. 2 CEO/Executive Director Statement Dear Friends, The IFOPA is a wonderful, grassroots organization that is committed to the lives of those suffering from this rare, neglected bone disorder, FOP. The FOP community is strong in its bond of finding a cure, however the rarity of FOP provides challenges in acquiring financial support until one understands the larger FOP research picture and how finding a cure for FOP may affect a multitude of other bone disorders. This community of those afflicted with FOP and their families are a true testament to the power of HOPE that resides in each of us. When you have an opportunity to meet them, you won't be the same. You will want to join us in this fight against time, so that we can stop the progression of bodies turning into bone. We invite you to come and learn more about the IFOPA! Board Chair Statement Dear Friends, The IFOPA takes pride in our financial efficiency, accountability to donors, and transparency. We work to use every dollar contributed as efficiently as possible. Historically, 80-90% of your contributions have gone toward funding medical research and member programs. The IFOPA’s support for medical research led to the FOP gene discovery in 2006. Our program dollars have funded four (4) International Symposia as well as numerous family gatherings and informational meetings, $40,000+ in LIFE Award scholarships to persons with FOP, the FOP Connection and Milestones publications, and more. We continue to financially support medical research, which is more important than ever as the FOP Lab and researchers at other academic institutions and pharmaceutical companies are narrowing in on potential treatment protocols. We are also developing new and better programs to support our members, with special attention to ensure access to those programs by those outside the United States. Thank you for supporting the IFOPA. Our pledge to donors is to continue to keep our overhead at or below the industry average, to maximize the percentage of your contributions that go to research and programs, and to spend our funds wisely so we can find treatments and a cure for FOP while supporting individuals and their families. We invite you to be a part of this herculean effort. Paul Brinkman Chairman of the Board Areas of Service Geographic Areas Served 3 Areas Internationally FL - Brevard FL - Lake FL - Orange FL - Osceola FL - Polk FL - Seminole FL - Volusia National We are the worldwide support organization for anyone that is diagnosed with Fibrodysplasia Ossificans Progressiva (FOP). Currently there are 800 FOP individuals worldwide representing over 60 countries. Service Categories Primary Organization Type Diseases Disorders & Medical Disciplines Secondary Organization Type Human Services 4 Programs Programs Medical Research Description Research is a significant part of the IFOPA’s mission and the key to solving the mystery of FOP. Research efforts can focus on a treatment and cure, including developing medications that alter not just the symptoms of the disease but the disease itself.The FOP Research Laboratory, created in 1992, is located at one of the most prestigious medical and research institutions in the country, the University of Pennsylvania School of Medicine. Led by Frederick Kaplan, M.D., and Eileen Shore, Ph.D., the FOP Research laboratory’s dedicated research team includes three principal investigators with many post-doctoral fellows, scientists, students and staff. This core team collaborates with physicians and scientists worldwide to develop treatments and, someday, a cure for FOP that of finding a treatment and a cure. Since the gene discovery in 2006, we are now closer than ever to reaching this goal. Supporting this program is critical not only to developing treatments for people with FOP, but to also unlocking the mysteries of many common skeletal conditions such as osteoporosis, osteoarthritis, post-amputation treatment, and specific complications of hip replacements, spinal cord injuries, head injuries and some heart valve disorders. Class Code Diseases, Disorders & Medical Disciplines, General/Other Class Sub Code Diseases, Disorders & Medical Disciplines, General/Other Population Served People/Families of People with Health Conditions People/Families with of People with Disabilities Budget $500,000.00 Long Term Success The long term success of research is that a treatment and/or cure is found for those suffering from FOP and other bone related illnesses. The discovery of the FOP gene in 2006, along with emerging insights into mediated heterotopic ossification reveals a new road map with at least four plausible approaches to disarming the FOP bomb. The mutant FOP gene encodes an overactive switch that needs to be "turned off" or more probably "turned down." When the FOP gene was discovered in 2006, there were no drugs available to turn-off the gene or effectively modulate its activity. Such lead compounds have now been indentified but may be too powerful and dangerous to use in humans. What we now have are compounds that can turn-off the damaged switch. What we need is a dimmer. Short Term Success Each year, new research strides are made at the FOP Lab at the University of Pennsylvania School of Medicine and by colleagues and collaborators around the world. These are documented in the IFOPA published Annual Report of the Fibrodysplasia Ossificans Progressiva (FOP) Collaborate Research Project. Program Success Monitored By Examples of Program Success The discovery of the FOP gene in 2006 is a perfect example of what the research dollars spent by the IFOPA are doing for FOP research. 5 L.I.F.E Awards Description The Quality of L.I.F.E. award, signifying Living Independently with Full Equality, is a program designed to assist people with FOP to live their lives more independently. The award provides up to $1,500.00 per person and is intended for use in purchasing items that improve the health, welfare and independence of members with FOP of all ages. Many members endure costly medical expenses and have a difficult time purchasing items that assist them with their everyday lives. Examples of such items include service dogs, wheelchairs, education or vocational training, wheelchair ramps or lifts, and therapeutic mattresses, among others.A gift to the IFOPA's Quality of L.I.F.E. Award Program allows you to directly impact the lives of FOP members desiring independence. Support to this program is critical to FOP members. Class Code Philanthropy, Voluntarism & Grantmaking, General/Other Class Sub Code Philanthropy, Voluntarism & Grantmaking, General/Other Population Served People/Families with of People with Disabilities Budget $6,000.00 Long Term Success The long term affect is that those with FOP are provided something that helps them to live their life more independently, and allows them to become a productive member of society. Short Term Success Program Success Monitored By Examples of Program Success Members with FOP have been provided funding to assist with: assistance service dogs, laptop computers, pool ramps, wheelchairs, college tuition and vehicle adaptations. 6 International Support Description The FOP community spans among 60+ countries worldwide. Of these 60+ countries, 55 do not speak English and remain unaware of research findings and support initiatives until they are translated into their native language. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations is the most important document a person with FOP can receive as it explains the necessary precautions and procedure protocols to ease the symptoms of FOP emergency treatment guidelines and instructions for handling a patient with FOP; an emergency USB flash drive to house important medical information; and a portable pill holder to carry an emergency dose of medication. Having personalized medical information readily at-hand helps to reduce stress and can provide the opportunity for our patients to receive better care. In order to provide all of these documents in each native language is an expense we need funding for so those with FOP are not isolated from the FOP community and from important medical information. Our international communities’ wish to host meetings for families in their regions. To hold such an event successfully, these communities need necessary funding as well as resources and educational materials translated into their language. To have the IFOPA website in several languages will improve the communication of information and resources for those with FOP in countries that do not speak English, as well as decrease the number of misdiagnoses and get those with FOP the proper care they need. Class Code Diseases, Disorders & Medical Disciplines, General/Other Class Sub Code Diseases, Disorders & Medical Disciplines, General/Other Population Served Other Named Groups Budget $0.00 Long Term Success The long term success is that those with FOP in every country of the world are properly diagnosed. The current misdiagnosis rate is over 85%. By reaching out to the medical community and FOP community in with materials in multiple languages, can help to reduce this extremely high rate of misdiagnosis and help to stop unneccessary medical procedures that quickly increase the effects of FOP. Short Term Success As the only organization worldwide devoted to FOP, we are able to immediately provide all those diagnosed with FOP relevant, important medical information so that they can properly manage their care. This requires the ability to provide the materials in multiple languages. Program Success Monitored By Examples of Program Success When you have grown up thinking you are the only person that is afflicted in such a way that you can not stand up, lift your arms over your head, brush your own teeth or sit down in a regular chair, you feel alone. The IFOPA has diminished the barriers that once existed by providing a community for everyone with FOP to come together. Now, there is support for each of our members to not feel alone anymore. 7 Public Awareness Description FOP is one of the rarest bone disorders known in the world. Very few people have heard of FOP, let alone know all that it entails -- including medical professionals. Increasing awareness among medical professionals, political officials, and the public at large is critical to serving our population. Increased awareness will result in additional funding for research and member programs, and should drastically reduce the number of devastating misdiagnoses. The IFOPA raises awareness through advocacy, through the dissemination of educational and treatment information on its website, in brochures and on DVDs, and by maximizing every media opportunity available to inform the public and the medical community about FOP. Class Code Diseases, Disorders & Medical Disciplines, General/Other Class Sub Code Diseases, Disorders & Medical Disciplines, General/Other Population Served General/Unspecified Budget $0.00 Long Term Success Short Term Success Program Success Monitored By Examples of Program Success Member Education & Support Description Support, both emotional and functional, is imperative to the health of those living with FOP as well as their families. Overcoming certain obstacles can often be as frustrating for family members as it is for the person affected. The IFOPA develops and drives various programs for our membership including but not limited to educational webinars, a website to educate families and medical professionals, a guidebook for families on how to cope with FOP, a mentoring system for those facing the difficulties of FOP, grants for independent living assistance, an online interactive communication system for members, and regional family and member symposiums and support meetings. Class Code Health Care, General/Other Class Sub Code Patient & Family Support Population Served General/Unspecified Budget $0.00 Long Term Success Short Term Success Program Success Monitored By Examples of Program Success 8 CEO Comments The International FOP Association's programs include the staffing and support of the FOP research laboratory at the University of Pennsylvania, where dedicated physicians and technical support race against time to discover a treatment, and perhaps a cure, for the devastating effects of FOP. The IFOPA also maintains a Resource Center of articles, videos, and scientific documents for the education of the general and medical community about FOP. Other key quality programs and services that are provided worldwide include educational webinars, a guidebook on FOP for families, a mentoring system, and funding for independence assistance, an interactive communication system for members, and regional family and member gatherings. 9 Impact Goals Our goal is to find a cure for Fibrodysplasia Ossificans Progressiva. Strategies Our strategy is to fund FOP research through continuous grassroots fundraising. With an extremely small patient community, we lack the means to mount high profile national campaigns, and instead rely primarily on local fundraising and donations from families and friends. We also work closely with international FOP communities to promote awareness and encourage international research efforts. We provide advice and support for patients and their families. Capabilities IFOPA employs an efficient and effective staff headquartered in Orlando, Florida. Governance is provided by an elected volunteer board of directors of nine to 15 members drawn from the USA and abroad. IFOPA provides a comprehensive website in more than 10 languages that includes a wide range of information regarding FOP research, disease treatments and family support. IFOPA provides an extensive Wikipedia article detailing the history of the association, our fundraising activities, and a variety of other information resources. Our Research Committee works closely with the FOP Lab at the University of Pennsylvania and with international research groups to coordinate research activities and support. Indicators Given our strong focus on fund-raising, total donations received are our primary indicator. In recent years, annual donations have been in the range of $1,000,000+. IFOPA is recognized as the primary research supporter of the FOP Lab at the University of Pennsylvania. Progress In its 28 year existence, IFOPA has donated over $18 million to FOP research, and currently donates approximately $500,000 annually. Net surpluses (funds remaining after expenses) are invested to establish long-term association stability and funding future drug trials. Net assets at the end of 2015 were approximately $4.2 million. There are currently two separate clinical trials underway by Clementia Pharmaceuticals and Regeneron Pharmaceuticals 10 Management CEO/Executive Director Executive Director Organization is Volunteer Lead Experience The organization is Volunteer lead. The IFOPA does not have a paid CEO or Executive Director Former CEOs Name Term Linda Daugherty 2001 - Feb 2010 Karen Revels 2010 - Feb 2011 Senior Staff Victoria Mandracken Title Communications and Membership Manager Experience/Biography Denise Vietti Title Operations Manager Experience/Biography Susie Weidner Title Accountant Experience/Biography Staff Full Time Staff 3 Part Time Staff 0 Volunteers 365 Contractors 3 Retention Rate 60% State Information State Charitable Solicitations Permit? Yes Mar 2017 State Registration Yes Mar 2017 Management Comments CEO/Executive Director/Board Comments 11 Plans & Policies Plans and Policies Organization has a Fundraising Plan? No Organization has a Strategic Plan? Under Development Management Succession Plan? No Organization Policy and Procedures Yes Nondiscrimination Policy Yes Directors and Officers Insurance Policy Yes Management Information Whistleblower Policy Yes Document Destruction Policy Yes Management Reports To Board Yes CEO/Executive Director Formal Evaluation N/A CEO/Executive Director Formal Frequency Annually Senior Management Formal Evaluation Yes Senior Management Formal Evaluation Frequency Annually Collaborations The IFOPA collaborates with and funds the FOP Laboratory at the University of Pennsylvania School of Medicine. The IFOPA collaborates with the US Bone and Joint Decade, The Rare Bone Disease Patient Network and the National Organization for Rare Disorders. 12 Governance Board Chair Board Chair Paul T Brinkman Company Affiliation Community Volunteer Term Jan 2016 to Dec 2017 Board CoChair Board CoChair Amy Gordon Company Affiliation Community Volunteer Term Jan 2016 to Dec 2017 Board Members Name Affiliation Status Chris Bedford-Gay Turtlez Ltd Voting Paul T Brinkman Retired Voting Amy Gordon Melton Sales Voting Moira Liljesthrom Community Volunteer Voting Joseph Martucci Community Volunteer Voting Gary McGuire US Dow Chemical Voting Karen Munro Community Volunteer Voting Rory Otto Community Volunteer Voting Nancy Sando Community Volunteer Voting Carol Tilley Retired Voting Gail Weakland Retired Voting Board Demographics - Ethnicity African American/Black 0 Asian American/Pacific Islander 0 Caucasian 10 Hispanic/Latino 1 Native American/American Indian 0 Other 00 Board Demographics - Gender Male 4 Female 7 Not Specified 0 Governance 13 Board Term Lengths 2 Board Term Limits 0 Board Meeting Attendance 89% Number of Full Board Meetings Annually 6 Written Board Selection Criteria? Yes Written Conflict of Interest Policy? Yes Percentage Making Monetary Contributions 75% Percentage Making In-Kind Contributions 100% Risk Management Provisions Directors and Officers Policy Employment Practices Liability Standing Committees Audit Board Development / Board Orientation Development / Fund Development / Fund Raising / Grant Writing / Major Gifts Finance Investment Program / Program Planning Communications / Promotion / Publicity / Public Relations 14 Financials Fiscal year Fiscal Year Start Jan 01, 2016 Fiscal Year End Dec 31, 2016 Projected Revenue $1,107,000.00 Projected Expenses $1,769,634.00 Endowment Value $0.00 Percentage 0% Detailed Financials Revenue and Expenses Fiscal Year Total Revenue Total Expenses Revenue Sources Fiscal Year Foundation and Corporation Contributions Government Contributions Federal State Local Unspecified Individual Contributions Indirect Public Support Earned Revenue Investment Income, Net of Losses Membership Dues Special Events Revenue In-Kind Other 2014 $1,830,617 $992,349 2013 $1,474,621 $837,893 2012 $934,532 $614,209 2014 $0 2013 $430,457 2012 $203,465 $0 $0 $0 $0 $0 $1,032,373 $0 $1,294 $34,004 $4,621 $713,528 $44,797 $0 $0 $0 $0 $0 $0 $554,827 $0 $3,228 $7,357 $6,850 $803,779 $98,580 $0 $0 $0 $0 $0 $0 $73,006 $0 $2,162 $9,471 $7,100 $598,272 $41,056 $0 15 Expense Allocation Fiscal Year Program Expense Administration Expense Fundraising Expense Payments to Affiliates Total Revenue/Total Expenses Program Expense/Total Expenses Fundraising Expense/Contributed Revenue Assets and Liabilities Fiscal Year Total Assets Current Assets Long-Term Liabilities Current Liabilities Total Net Assets Short Term Solvency Fiscal Year Current Ratio: Current Assets/Current Liabilities Long Term Solvency Fiscal Year Long-Term Liabilities/Total Assets 2014 $837,115 $94,259 $60,975 $0 1.84 84% 3% 2013 $673,843 $99,099 $64,951 $0 1.76 80% 4% 2012 $476,709 $72,818 $64,682 $0 1.52 78% 7% 2014 $3,486,104 $961,365 $0 $87,504 $3,398,600 2013 $2,563,142 $2,552,629 $0 $17,008 $2,546,134 2012 $1,915,094 $1,679,562 $0 $9,743 $1,905,351 2014 10.99 2013 150.08 2012 172.39 2014 0% 2013 0% 2012 0% 2013 Special Events $803,779 2012 Special Events $598,272 Foundations and Corporations $430,457 Individuals $124,370 Foundations, Corporations $203,465 Individuals $73,006 Top Funding Sources Fiscal Year Top Funding Source & Dollar Amount 2014 Foundations, Corporations and Individuals $1,032,373 Second Highest Funding Source & Dollar Special Events Amount $713,528 Third Highest Funding Source & Dollar Amount In-Kind $44,797 Capital Campaign Currently in a Capital Campaign? No Goal 0 Comments Foundation Comments Financial figures taken from IRS Form 990. 990 and audit are reconciled. In-kind revenue includes noncash reported on IRS form 990. 16 Disaster Plans Disaster Plans Organization is a member of Voluntary Organizations Active in Disaster (VOAD)? Created 10.29.2016. No Copyright © 2016 Central Florida Foundation 17